BofA lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $9 from $10 and keeps a Buy rating on the shares. While stating that “there wasn’t much new from Werewolf’s 1Q print,” the firm still sees reasons to be encouraged about the second half outlook, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Receives Nasdaq Deficiency Notice
- Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating
- Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush
- Werewolf Therapeutics Reports Q1 2025 Financial Results
- Werewolf Therapeutics files $150M mixed securities shelf
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue